- Optimi Health Corp. (OPTI) has submitted a request to Health Canada for an amendment to its Controlled Substances Dealer’s Licence
- The amendment would enable the company to synthesize, process and distribute pharmaceutical grade 3,4-Methylenedioxymethamphetamine (MDMA), among other substances, at its Princeton, British Columbia facility
- The company plans to move to expand its offering to encompass a wide variety of synthetic psychedelics through its EU-GMP cultivation and analytical laboratory
- Optimi Health Corp. is a homegrown company producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms
- Optimi Health Corp (OPTI) was up 4.17 per cent, trading at $0.25 at 10:45 ET
Optimi Health Corp. (OPTI) has submitted a request for an amendment to its Controlled Substances Dealer’s Licence to Health Canada.
The amendment would enable the company to synthesize, process and distribute pharmaceutical grade 3,4-Methylenedioxymethamphetamine (MDMA), among other substances, at its Princeton, British Columbia facility.
With the company’s main capital expenditure now completed, it will move to expand its offering to encompass a wide variety of synthetic psychedelics through its market-leading EU-GMP cultivation and analytical laboratory.
This aligns with Optimi’s planned year of commercialization, allowing the company to maximize revenue-generating opportunities through standardized psychedelic drug testing, R&D, and product development through approved clinical trials and exemption-based applications.
Ongoing large-scale studies, including Phase III clinical trials investigating MDMA conducted by the Multidisciplinary Association for Psychedelic Studies (MAPS), along with more recent decriminalization initiatives announced in the Province of British Columbia, have generated significant unmet demand for these substances for research purposes.
“We are filing this amendment following conversations with researchers and drug developers which have led to a high volume of requests for GMP-compliant synthetic psychedelics,” stated Optimi CEO, Bill Ciprick.
“The positive reports from trauma sufferers, including veterans groups, for whom substances such as MDMA might make a difference, mean that safe, scalable supply is going to be more crucial than ever to the success of psychedelic medicine,” he added.
Optimi Health Corp. is a homegrown company producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms that focus on the health and wellness markets.
Optimi Health Corp (OPTI) was up 4.17 per cent, trading at $0.25 at 10:45 ET.
